X4 Pharmaceuticals: FDA Approval For WHIM Warrants Further Upside
Summary: - X4 Pharmaceuticals' mavorixafor FDA approval for WHIM syndrome and receipt of a priority review voucher. - Premium pricing for mavorixafor at $496K annually for patients >50kg and $372K for patients ≤50kg. - XFOR's financials report $115.2 million in cash as of December 31, 2023. Price Impact Rating: Bullish Impact Horizon Rating: Long-term Type: Research Analysis
View signal analysis